Phase 2Not yet recruitingAge-related condition

A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema

Sponsor
SciNeuro (Industry)
Enrollment
60 planned
Conditions
Diabetic Macular Edema; DME
Interventions
SNP318; Placebo
Ages
adults, older adults
Registry
NCT07199777

Full record on ClinicalTrials.gov

From the registry

The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.

Primary outcomes

  • Safety Events
  • Central Subfield Thickness (CST)

History

  1. Study completion expected

  2. Primary completion

  3. Started

  4. Registered